Menu
Search
|

Menu

Close
X

Dicerna Pharmaceuticals Inc DRNA.OQ (NASDAQ Stock Exchange Global Select Market)

14.33 USD
+0.13 (+0.92%)
As of 4:00 PM EDT
Previous Close 14.20
Open 14.20
Volume 132,351
3m Avg Volume 164,641
Today’s High 14.45
Today’s Low 14.16
52 Week High 17.96
52 Week Low 9.40
Shares Outstanding (mil) 68.32
Market Capitalization (mil) 970.20
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.67 Mean rating from 9 analysts

KEY STATS

Revenue (mm, USD)
FY19
3
FY18
6
FY17
1
FY16
0
EPS (USD)
FY19
-0.383
FY18
-1.620
FY17
-3.665
FY16
-2.873
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.23
Price to Sales (TTM)
vs sector
125.38
10.86
Price to Book (MRQ)
vs sector
5.40
4.40
Price to Cash Flow (TTM)
vs sector
--
24.08
Total Debt to Equity (MRQ)
vs sector
0.00
18.12
LT Debt to Equity (MRQ)
vs sector
0.00
12.99
Return on Investment (TTM)
vs sector
-49.87
12.65
Return on Equity (TTM)
vs sector
-74.34
17.19

EXECUTIVE LEADERSHIP

J. Kevin Buchi
Independent Chairman of the Board, Since 2019
Salary: --
Bonus: --
Douglas Fambrough
President, Chief Executive Officer, Director, Since 2010
Salary: $507,150.00
Bonus: --
John Green
Chief Financial Officer, Principal Financial Officer, Since 2016
Salary: $388,125.00
Bonus: --
Bob Brown
Senior Vice President, Chief Scientific Officer, Since 2012
Salary: $414,000.00
Bonus: --
Regina Paglia
Senior Vice President of Human Resources, Since 2019
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

87 Cambridgepark Dr
CAMBRIDGE   MA   02140-2311

Phone: +1617.6218097

Dicerna Pharmaceuticals, Inc. is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. It is focused on development of RNAi-based therapeutics using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases and cardiovascular diseases. Its development programs include dacryocystorhinostomy (DCR)-PHXC for the treatment of primary hyperoxaluria (PH), which is in a Phase I clinical trial; DCR-HBVS for the treatment of chronic hepatitis B virus (HBV), which is in a Phase I clinical trial, and a product candidate against a rare liver disease. It also developed a wholly owned clinical candidate, DCR-BCAT, targeting the β-catenin oncogene. DCR-BCAT is delivered by its lipid nanoparticle (LNP) tumor delivery system, EnCore.

SPONSORED STORIES